The ASCO 2026 presentation of the 500-patient trial led by Dana-Farber reported median overall survival of 13.2 months with daily daraxonrasib versus 6.6–6.7 months with chemotherapy in previously treated metastatic pancreatic ductal adenocarcinoma (NCT identifier pending, ASCO abstract LBA). The Ras(On) multi-selective inhibitor produced objective responses in 29 % of patients and grade ≥3 adverse events in 38 %, lower than the chemotherapy arm. Kras G12 mutations were confirmed in 92 % of enrolled cases, aligning with prior genomic surveys (Bailey et al., Nature 2016).